Glucose intolerance: the hidden danger in hypertensives!

A M Salmasi1, M Dancy

  • 1Hypertension Clinic and the Cardiac Research Unit, Central Middlesex Hospital, London, UK. majeed.salmasi@nwlh.nhs.uk

Insights

Systemic hypertension and glucose intolerance significantly increase cardiovascular risk. Early detection of unrecognised glucose metabolism abnormalities in hypertensive patients via oral glucose tolerance tests is crucial for effective management and risk assessment.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Systemic hypertension and abnormal glucose metabolism are independent cardiovascular risk factors.
  • Their coexistence exacerbates cardiovascular morbidity and mortality.
  • Both conditions contribute to arterial stiffness and cardiac remodeling, including left ventricular hypertrophy and diastolic dysfunction.

Purpose of the Study:

  • To highlight the high prevalence of unrecognised glucose metabolism abnormalities in hypertensive patients.
  • To emphasize the inadequacy of current screening methods (fasting plasma glucose, HbA1c) for detecting these abnormalities.
  • To advocate for the routine use of oral glucose tolerance tests in hypertensive patients.

Main Methods:

  • Analysis of oral glucose tolerance test (OGTT) results in patients with systemic hypertension.
  • Comparison of OGTT findings with fasting plasma glucose and glycated haemoglobin levels.
  • Assessment of cardiovascular risk associated with coexisting hypertension and glucose intolerance.

Main Results:

  • 58% of hypertensive patients without a known cardiac history or diabetes have unrecognised glucose metabolism abnormalities (diabetes or impaired glucose tolerance).
  • Fasting plasma glucose and HbA1c lack sensitivity for diagnosing diabetes and cannot identify impaired glucose tolerance in this population.
  • Underestimation of cardiovascular risk occurs when glucose intolerance is not identified.

Conclusions:

  • Oral glucose tolerance tests are essential for early detection of glucose metabolism abnormalities in hypertensive patients.
  • Early identification enables appropriate management and primary preventative measures.
  • Routine OGTT screening in hypertension clinics is recommended to accurately assess cardiovascular risk.

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...